How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.

about

Risk of bias in model-based economic evaluations: the ECOBIAS checklist.

P2860

Q30252032-A5B2A86C-736C-4E7A-B25C-D926E9A7EC24

P2860

How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q38185992

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

How to select the right cost-e ...... odel for rheumatoid arthritis.

@en

type

Item

label

How to select the right cost-e ...... odel for rheumatoid arthritis.

@en

prefLabel

How to select the right cost-e ...... odel for rheumatoid arthritis.

@en

P1476

How to select the right cost-e ...... model for rheumatoid arthritis

@en

P2093

A Boonen

http://www.w3.org/2001/XMLSchema#string

H G M van Haalen

http://www.w3.org/2001/XMLSchema#string

J L Severens

http://www.w3.org/2001/XMLSchema#string

P2860

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.

Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data.

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype

Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain.

Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application.

Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

P2888

s40273-014-0139-9

P304

429-442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-014-0139-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

An Tran-Duy

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24504853

http://www.w3.org/2001/XMLSchema#string

How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.

about

P2860

P2860

How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698